The development of new techniques and improvements has markedly increased success rates and the overall birth rates
Our History and Development
The PIVET IVF program commenced in 1981 following the return of PIVET’s Medical Director, Professor John Yovich who had completed four years in London and Cambridge studying all the new developments in Gynaecology, Andrology and Reproductive Medicine. The first IVF infant born in Western Australia in July 1982 was from the PIVET program.
As a pioneer unit PIVET experienced all of the adverse effects of ovarian stimulation, IVF and laparoscopic surgeries in the early evolution days; this included multiple pregnancies, cases of OHSS (Ovarian Hyperstimulation syndrome), some cases of ectopic and even heterotopic (combined tubal & uterine) pregnancies, as well as rarer events such as ovarian torsion and pelvic infections. However PIVET also introduced solutions to all of these problems to make them nowadays extremely rare.
Laboratory techniques for IVF have advanced so well and implantation rates are now very high from simple uterine transfer. With these improvements PIVET has moved to become a very successful SET (single embryo transfer) clinic. Nowadays 97% of all PIVET pregnancies are singleton and this associates with improved pregnancy gestations and higher birth weights than previously. In the last decade PIVET introduced specific Algorithms to ensure that each woman receives the precise dosage of ovarian hormone stimulants to ensure egg collection is in the safe range.
With the improvements in embryo culture and vitrification, many European clinics are moving to the idea of cryopreservation of all top quality blastocysts. The published data from PIVET shows that the pregnancy rates are indeed higher and this can be a good way to move forward. The problem for fresh cycles has been finding the ideal luteal support system and although PIVET is in the advance of studies in this area, the use of FET in natural cycles and HRT controlled cycles gives outstanding higher results.
Along with this is now the idea of extending the new knowledge in genetics including SNP (single nucleotide polymorphism) and NGS (next generation sequencing) screening of all blastocysts to identify the few which have normal chromosomes and genetic profile. This opens up very advanced ideas for the future of human reproduction generally and a mechanism to reduce fetal and infant anomalies.
PIVET is also now involved in research to improve the chances of successful pregnancy for women of advanced maternal age as the current results for women aged over 42 years is rather poor, but many women are trying to conceive in this pre-menopausal age range. The new research involves studies in molecular biology trying to slow down the release of oocytes from the primordial follicle pool. Other new research overseas looks at storing ovarian tissue from young women and returning this back to them when their own ovarian function begins to fade. In the meantime we are encouraging young women (under 34 years) who wish to defer pregnancy to put oocytes in storage as a form of egg banking for future use. This is already being encouraged for young women facing chemotherapy and radiotherapy for various cancers.